Ganga Pharmaceuticals Ltd
Incorporated in 1989, Ganga Pharmaceuticals Ltd is in the business of manufacturing & trading in Ayurvedic pharmaceuticals & allied products[1]
- Market Cap ₹ 7.15 Cr.
- Current Price ₹ 14.8
- High / Low ₹ 27.1 / 9.25
- Stock P/E 89.4
- Book Value ₹ 14.7
- Dividend Yield 0.00 %
- ROCE 3.18 %
- ROE 1.13 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.00 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -2.46% over past five years.
- Company has a low return on equity of 0.91% over last 3 years.
- Promoter holding has decreased over last 3 years: -10.7%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2.66 | 2.44 | 2.45 | 2.63 | 2.73 | 3.18 | 2.99 | 2.27 | 2.32 | 2.47 | 2.74 | 2.64 | |
2.43 | 2.19 | 2.15 | 2.32 | 2.41 | 2.76 | 2.61 | 2.24 | 2.28 | 2.47 | 2.69 | 2.76 | |
Operating Profit | 0.23 | 0.25 | 0.30 | 0.31 | 0.32 | 0.42 | 0.38 | 0.03 | 0.04 | 0.00 | 0.05 | -0.12 |
OPM % | 8.65% | 10.25% | 12.24% | 11.79% | 11.72% | 13.21% | 12.71% | 1.32% | 1.72% | 0.00% | 1.82% | -4.55% |
0.15 | 0.17 | 0.14 | 0.16 | 0.15 | 0.14 | 0.17 | 0.25 | 0.26 | 0.30 | 0.24 | 0.44 | |
Interest | 0.30 | 0.33 | 0.33 | 0.32 | 0.28 | 0.25 | 0.24 | 0.19 | 0.19 | 0.19 | 0.18 | 0.18 |
Depreciation | 0.03 | 0.04 | 0.04 | 0.04 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 |
Profit before tax | 0.05 | 0.05 | 0.07 | 0.11 | 0.13 | 0.26 | 0.26 | 0.04 | 0.06 | 0.05 | 0.06 | 0.09 |
Tax % | 40.00% | 40.00% | 28.57% | 27.27% | 23.08% | 30.77% | 23.08% | 50.00% | 16.67% | 40.00% | 33.33% | 11.11% |
0.03 | 0.03 | 0.05 | 0.07 | 0.09 | 0.19 | 0.19 | 0.02 | 0.04 | 0.04 | 0.05 | 0.08 | |
EPS in Rs | 0.13 | 0.13 | 0.12 | 0.17 | 0.22 | 0.47 | 0.47 | 0.05 | 0.10 | 0.10 | 0.10 | 0.17 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 1% |
5 Years: | -2% |
3 Years: | 4% |
TTM: | -4% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | -16% |
3 Years: | 26% |
TTM: | 60% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 16% |
3 Years: | 13% |
1 Year: | -40% |
Return on Equity | |
---|---|
10 Years: | 2% |
5 Years: | 1% |
3 Years: | 1% |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 2.33 | 2.33 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.84 | 4.84 |
Reserves | 0.28 | 0.31 | 0.74 | 0.81 | 0.91 | 1.09 | 1.29 | 1.31 | 1.35 | 1.39 | 2.21 | 2.29 |
2.07 | 2.14 | 2.19 | 2.14 | 2.05 | 1.87 | 1.47 | 1.73 | 1.93 | 1.83 | 1.36 | 1.42 | |
0.46 | 0.61 | 0.35 | 0.60 | 1.22 | 0.74 | 0.75 | 0.56 | 0.66 | 0.71 | 0.24 | 0.42 | |
Total Liabilities | 5.14 | 5.39 | 7.34 | 7.61 | 8.24 | 7.76 | 7.57 | 7.66 | 8.00 | 7.99 | 8.65 | 8.97 |
0.65 | 0.65 | 0.62 | 0.62 | 0.82 | 0.80 | 0.76 | 0.72 | 0.68 | 0.64 | 0.61 | 0.66 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.05 | 0.05 | 0.50 | 0.00 | 0.00 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.00 |
4.44 | 4.69 | 6.22 | 6.99 | 7.42 | 6.87 | 6.72 | 6.85 | 7.23 | 7.26 | 7.95 | 8.31 | |
Total Assets | 5.14 | 5.39 | 7.34 | 7.61 | 8.24 | 7.76 | 7.57 | 7.66 | 8.00 | 7.99 | 8.65 | 8.97 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.21 | 0.27 | -1.05 | 0.05 | 0.24 | 0.11 | -0.31 | -0.18 | -0.21 | -0.04 | -1.26 | -0.58 | |
-0.23 | -0.18 | -0.83 | 0.62 | -0.14 | 0.28 | 0.37 | 0.28 | 0.19 | 0.49 | 0.13 | 1.18 | |
0.43 | -0.06 | 1.90 | -0.33 | -0.36 | -0.45 | -0.29 | -0.10 | 0.03 | -0.44 | 1.14 | -0.33 | |
Net Cash Flow | -0.01 | 0.03 | 0.02 | 0.33 | -0.26 | -0.05 | -0.22 | 0.00 | 0.01 | 0.01 | 0.00 | 0.27 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 94.68 | 109.20 | 140.04 | 173.48 | 211.25 | 141.18 | 130.62 | 131.85 | 140.02 | 131.52 | 122.55 | 125.81 |
Inventory Days | 312.46 | 288.16 | 374.86 | 385.66 | 358.71 | 341.26 | 296.56 | 332.62 | 330.51 | 347.34 | 362.08 | 353.03 |
Days Payable | 105.08 | 118.01 | 98.65 | 182.50 | 330.39 | 163.21 | 159.69 | 129.52 | 152.32 | 170.73 | 29.20 | 83.77 |
Cash Conversion Cycle | 302.07 | 279.35 | 416.26 | 376.64 | 239.56 | 319.23 | 267.49 | 334.96 | 318.21 | 308.13 | 455.43 | 395.08 |
Working Capital Days | 222.29 | 233.36 | 597.41 | 428.84 | 417.14 | 387.96 | 449.23 | 619.05 | 667.07 | 653.16 | 730.00 | 851.67 |
ROCE % | 7.87% | 8.03% | 6.80% | 6.14% | 5.84% | 7.26% | 7.23% | 3.30% | 3.46% | 3.28% | 3.06% | 3.18% |
Documents
Announcements
-
Statement Of Deviation And Variation
1d - No deviation in utilization of Rs.1.70 Cr raised via preferential issue as of Mar 31, 2025.
-
Results
1d - Audited financial results for FY ended March 31, 2025, with net profit of Rs.7.90 lakhs and unmodified auditor opinion.
-
Board Meeting Outcome for Held On May 20, 2025
1d - Audited financial results for FY ended March 31, 2025 with unmodified audit opinion disclosed.
-
Board Meeting Intimation for Consideration And Approval Of The Audited Financial Results For The Half And Financial Year Ended On March 31 2025.
6 May - Board meeting on May 20 to approve audited financial results for FY ending March 31, 2025.
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
22 Apr - Resignation of Company Secretary Ms. Priti Kothari Bhaiya effective April 22, 2025 due to personal reasons.
Annual reports
Concalls
-
May 2024TranscriptNotesPPT
Business Overview:[1][2]
Company does production of Ayurvedic Medicines by using techniques strictly as per Ancient text and Ayurved pharma companies. Apart from manufacturing, it is also into marketing and distribution of Bulk Ayurvedic Medicines in Mumbai